Our findings suggest that clinical trials investigating the efficacy of drugs such as tocilizumab (IL-6R antagonist that targets all IL-6 signalling modalities), olamkicept (soluble gp130Fc that blocks IL-6 trans-signalling) and low-dose aldesleukin (IL-2 analogue) may be promising candidates for the prevention of type 1 diabetes. The gene discussed is IL6R; the disease is type 1 diabetes mellitus.